Results 1 to 10 of about 2,461,363 (302)

Single versus Dual Antiplatelet Therapy in Prevention of Early Stroke Recurrence after the First Acute Ischemic Stroke [PDF]

Zagazig University Medical Journal
Background: The dual antiplatelet therapy effectiveness compared with single antiplatelet therapy among acute non-cardioembolic ischemic stroke patients is still debated, especially as regards of functional outcomes, survival rates, and bleeding risks ...
El-Hady Abd El Gawwad, Tarek Goda, Eman Mansour, Nancy Mohamed   +3 more
doaj   +1 more source

Dual Antiplatelet Therapy in Patients With Minor Stroke Receiving Intravenous Thrombolysis

Frontiers in Neurology, 2022
IntroductionConcern over the potential severe bleeding risk of dual antiplatelet therapy for patients with minor stroke after intravenous thrombolysis (IVT) leads to different antiplatelet strategies in the secondary prevention of stroke.
Zhaohan Xu, Nihong Chen, Nihong Chen, Huiling Sun, Teng Jiang, Qiwen Deng, Junshan Zhou, Yingdong Zhang   +7 more
doaj   +1 more source

Pharmacogenetics of Antiplatelet Therapy

Annual Review of Pharmacology and Toxicology, 2023
Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of ...
Matteo, Castrichini, Jasmine A, Luzum, Naveen, Pereira   +2 more
openaire   +2 more sources

Outcomes of Severe Sepsis and Septic Shock Patients on Chronic Antiplatelet Treatment: A Historical Cohort Study

Critical Care Research and Practice, 2013
Background. Sepsis is characterized by dysfunctional activation of platelets, and antiplatelet therapy could improve the outcomes of septic patients. Methods.
Juan C. Valerio-Rojas, Insara J. Jaffer, Daryl J. Kor, Ognjen Gajic, Rodrigo Cartin-Ceba   +4 more
doaj   +1 more source

Pulmonary hemorrhage in patients receiving anti-platelets- a case series and a suggested therapeutic algorithm

Respiratory Medicine Case Reports, 2022
Antiplatelet therapy including aspirin and thienopyridine agents (such as clopidogrel, prasugrel and ticagrelor) are often used in patients with coronary disease.
Ioannis Tomos, Maria Kallieri, Andriana I. Papaioannou, Eleni Stagaki, Thomas Raptakis, Anna Karakatsani, Panagiotis Korkonikitas, Effrosyni D. Manali, Vagia Karageorgou, Myrto Mplizou, Katerina Vlami, Stelios Loukides, Spyros Papiris   +12 more
doaj   +1 more source

Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials

BMC Cardiovascular Disorders, 2021
Background We performed a meta-analysis sought to investigate the risk of stroke with antiplatelet and anticoagulant therapies among patients with coronary artery disease (CAD).
Qiao Yu Shao, Zhi Jian Wang, Xiao Teng Ma, Xu Ze Lin, Liu Pan, Yu Jie Zhou   +5 more
doaj   +1 more source

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, George A. Stouffer, Craig R. Lee, Craig R. Lee   +5 more
doaj   +1 more source

The CLEAR (Considering Leading Experts’ Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention

CVIR Endovascular, 2019
Background Antiplatelet and anticoagulant therapy are commonly used before, during and after peripheral arterial endovascular intervention. This survey aimed to establish antiplatelet and anticoagulant choice for peripheral arterial endovascular ...
Kitty H. F. Wong, Dave C. Bosanquet, Graeme K. Ambler, Mahim I. Qureshi, Robert J. Hinchliffe, Christopher P. Twine, CLEAR survey collaborators   +6 more
doaj   +1 more source

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Platelets, 2020
Cytochrome P450 (CYP) 2C19 genotype is closely associated with the metabolism and efficacy of clopidogrel, thereby having an important impact on clinical outcomes of patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary ...
Si-Qi Lyu, Yan-Min Yang, Jun Zhu, Juan Wang, Shuang Wu, Han Zhang, Xing-Hui Shao, Jia-Meng Ren   +7 more
doaj   +1 more source

Outcomes in Antiplatelet‐Associated Intracerebral Hemorrhage in the TICH‐2 Randomized Controlled Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain.
Zhe Kang Law, Michael Desborough, Ian Roberts, Rustam Al‐Shahi Salman, Timothy J. England, David J. Werring, Thompson Robinson, Kailash Krishnan, Robert Dineen, Ann Charlotte Laska, Nils Peters, Juan Jose Egea‐Guerrero, Michal Karlinski, Hanne Christensen, Christine Roffe, Daniel Bereczki, Serefnur Ozturk, Jegan Thanabalan, Rónán Collins, Maia Beridze, Philip M. Bath, Nikola Sprigg   +21 more
doaj   +1 more source